Financial Performance - The company's operating revenue for Q1 2023 was ¥134,510,760.91, representing a year-on-year increase of 93.55%[5] - The net profit attributable to shareholders for the same period was ¥53,818,215.08, reflecting a growth of 104.21% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 197.43% to ¥45,956,269.24[5] - Basic earnings per share for Q1 2023 were ¥0.40, up by 52.13% from the previous year[6] - Total operating revenue for Q1 2023 reached CNY 134,510,760.91, a significant increase of 93.8% compared to CNY 69,495,587.09 in Q1 2022[20] - Net profit for Q1 2023 was CNY 53,818,215.08, representing a 104.5% increase from CNY 26,353,868.93 in Q1 2022[21] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.40, compared to CNY 0.26 in Q1 2022[22] - The total comprehensive income for Q1 2023 was CNY 53,818,215.08, compared to CNY 26,353,868.93 in Q1 2022[22] Cash Flow - The net cash flow from operating activities was negative at -¥28,770,855.36, a decline of 320.02% year-on-year[5] - The net cash flow from operating activities was -28,770,855.36, compared to 13,076,633.59 in the previous year, indicating a significant decline in operational performance[24] - The net cash inflow from investment activities was 120,822,998.46, a recovery from a net outflow of -54,848,287.23 in the same period last year[25] - The cash inflow from investment activities totaled 1,105,376,495.33, significantly higher than 55,939,251.38 in the previous year[24] - The cash outflow from operating activities was 90,614,118.03, compared to 78,818,089.63 in the previous year, reflecting increased operational costs[24] - The cash outflow from financing activities was 11,023,130.56, compared to 344,798.20 in the previous year, indicating a rise in financing costs[25] - The company received tax refunds amounting to 3,435,036.98, compared to 506,792.64 in the previous year, showing improved tax recovery[24] - The cash inflow from other operating activities was 6,048,326.24, down from 13,081,049.11 in the previous year, indicating a decrease in operational revenue sources[24] - The company paid 18,729,896.89 in taxes, significantly higher than 6,171,222.97 in the previous year, reflecting increased tax liabilities[24] - The net cash flow from financing activities was -10,997,575.01, compared to 9,655,201.80 in the previous year, indicating a shift towards negative financing cash flow[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,864,911,749.38, down 4.00% from the end of the previous year[6] - As of March 31, 2023, the company's total assets amounted to RMB 1,864,911,749.38, a decrease from RMB 1,942,574,342.50 as of December 31, 2022, reflecting a decline of approximately 4.0%[15] - The company's cash and cash equivalents increased to RMB 456,138,765.13 from RMB 388,670,421.76, representing a growth of about 17.4%[15] - Inventory balance stood at RMB 75,075,863.29, slightly up from RMB 74,795,425.34, indicating a marginal increase of 0.4%[15] - The company reported a total of RMB 977,728,294.17 in trading financial assets, down from RMB 1,114,638,212.12, marking a decrease of approximately 12.3%[15] - The total non-current assets amounted to RMB 207,038,386.81, a slight increase from RMB 205,065,146.22, reflecting a growth of about 0.5%[16] - The company's accounts receivable decreased to RMB 123,451,670.42 from RMB 124,314,691.31, showing a decline of approximately 0.7%[15] - The company has a total of RMB 60,189,321.18 in accounts payable, down from RMB 69,194,598.89, indicating a decrease of about 13.5%[16] - The company’s total current liabilities include RMB 22,843,976.35 in contract liabilities, reflecting a significant reduction from RMB 105,103,823.64[16] - The company has a total of RMB 18,508,225.55 in long-term equity investments, indicating a stable investment strategy[16] Research and Development - R&D investment totaled ¥9,987,729.18, accounting for 7.43% of operating revenue, a decrease of 8.22 percentage points[6] - Research and development expenses for Q1 2023 were CNY 9,987,729.18, slightly down from CNY 10,875,959.08 in Q1 2022[21]

证券代码：688253 证券简称：英诺特 公告编号：2023-015 北京英诺特生物技术股份有限公司 关于召开 2022 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 04 月 13 日（星期四）下午 15:00-16:00 1 / 3 会议召开时间：2023 年 04 月 13 日（星期四）下午 15:00-16:00 会议召开地点： 上海证券 交易所上证路演中心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 04 月 06 日（星期四）至 04 月 12 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year 2022, representing a growth of 15% compared to the previous year[24]. - The company's operating revenue for 2022 was approximately ¥446.62 million, representing a year-over-year increase of 36.62% compared to ¥326.91 million in 2021[25]. - Net profit attributable to shareholders for 2022 was approximately ¥150.68 million, a 25.31% increase from ¥120.25 million in 2021[28]. - The net profit excluding non-recurring gains and losses for 2022 was approximately ¥132.49 million, reflecting a 22.00% increase from ¥108.60 million in 2021[25]. - The company's total assets at the end of 2022 reached approximately ¥1.94 billion, a 143.47% increase from ¥797.87 million at the end of 2021[26]. - The company's net assets attributable to shareholders increased by 128.85% year-over-year, reaching approximately ¥1.69 billion in 2022[28]. - The company achieved a revenue of 447 million yuan in 2022, representing a year-on-year growth of 36.62%[40]. - The company reported a foreign exchange gain of approximately ¥42.65 million in 2022, which accounted for 25.93% of the total profit for the year[28]. - The company reported a significant increase in cash flow from financing activities, totaling CNY 815.78 million, a rise of 1,470.01%[118]. - The company reported a net profit margin of 656.38 million, indicating strong profitability[177]. Research and Development - The company is investing in R&D for new technologies, with a budget allocation of 200 million RMB for the upcoming year, focusing on enhancing diagnostic accuracy[24]. - Research and development expenses accounted for 16.16% of operating revenue in 2022, up from 9.52% in 2021, indicating a significant increase in investment in innovation[27]. - Total R&D expenses increased by 132.00% year-over-year, reaching approximately ¥72.18 million, driven by higher personnel costs and an increase in ongoing projects[82]. - The company has established six major technology platforms, including PCR detection and recombinant protein engineering, to enhance its R&D capabilities[91]. - The company has developed a specific antibody detection technology that reduces non-specific reactions caused by endogenous interfering substances[76]. - The company has been expanding its R&D capabilities since 2020, with a dedicated R&D platform director overseeing new projects[183]. - The company is focusing on expanding its product offerings in the immunodiagnostic field, utilizing advanced detection methods for various diseases[85]. Product Development and Launches - New product launches included a respiratory joint detection kit, which has received regulatory approval and is expected to contribute significantly to future sales[24]. - The company successfully launched new combined detection products for respiratory pathogens, including influenza and norovirus tests[39]. - The company has developed a unique nine-in-one respiratory fluorescence test kit, which detects IgM antibodies for nine different pathogens[50]. - The company has developed a new COVID-19 IgM/IgG antibody test kit that provides a supplementary diagnostic tool for suspected cases with negative nucleic acid tests[51]. - The company is actively pursuing new product development and clinical trials, with several projects in various stages of completion[86]. Market Expansion and Strategy - Market expansion plans include entering three new international markets by the end of 2023, aiming for a 5% market share in each[24]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence, with a target of identifying at least two candidates by mid-2023[24]. - The company plans to expand its marketing network both domestically and internationally, with a focus on establishing overseas marketing centers in Southeast Asia, particularly Thailand[161]. - The company aims to enhance its market position through strategic R&D investments and product development initiatives[82]. - The company plans to enter the European market in the next quarter, targeting a revenue contribution of $20 million in the first year[180]. Corporate Governance and Management - The company has maintained compliance with corporate governance regulations and continuously improved its governance structure[168]. - The company appointed a new independent director in February 2023, enhancing its governance structure[181]. - The company has a diverse board with members holding positions in various sectors, enhancing its strategic insights[187]. - The company has not reported any significant differences in governance compared to regulatory requirements[168]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 5.624 million RMB[190]. Risks and Challenges - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8]. - The company faces risks related to macroeconomic conditions and potential impacts from healthcare reforms, which could affect product pricing and sales strategies[111]. - The company is at risk of losing key technical personnel, which could adversely affect its R&D progress and innovation capabilities[99]. - The company has implemented strict quality control processes and obtained various quality certifications, but still faces risks related to product quality management[105]. - The company highlighted financial risks related to currency fluctuations and the potential impact on future performance[140].

Financial Performance - The company's operating revenue for Q3 2022 was ¥60,738,932.35, representing a year-on-year increase of 28.46%[5] - Net profit attributable to shareholders for Q3 2022 reached ¥19,122,888.22, a significant increase of 103.79% compared to the same period last year[5] - Basic earnings per share for Q3 2022 were ¥0.17, up by 83.41% compared to the previous year[6] - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥17,837,044.36, showing a growth of 100.40% year-on-year[5] - Total operating revenue for the first three quarters of 2022 reached ¥310,532,891.94, an increase of 17.5% compared to ¥264,373,449.86 in the same period of 2021[20] - Net profit for the third quarter of 2022 was ¥127,691,880.56, representing a 21.8% increase from ¥104,807,601.60 in the same quarter of 2021[22] - The company reported a total profit of ¥141,498,773.22 for the third quarter of 2022, up from ¥120,027,545.15 in the same quarter of 2021[22] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥1,778,414,890.73, reflecting a year-on-year growth of 122.89%[6] - As of September 30, 2022, the total assets of the company amounted to ¥1,778,414,890.73, a significant increase from ¥797,873,232.31 at the end of 2021[14] - The total current liabilities reached ¥103,011,407.31, up from ¥52,147,430.34, marking an increase of about 97.5%[17] - Total liabilities increased to ¥112,070,174.03 in Q3 2022 from ¥59,703,304.99 in Q3 2021, reflecting a growth in financial obligations[21] - The total equity attributable to shareholders at the end of the reporting period was ¥1,666,344,716.70, an increase of 125.74% compared to the previous year[6] - Shareholder equity rose to ¥1,666,344,716.70 in Q3 2022, compared to ¥738,169,927.32 in Q3 2021, indicating strong financial health[21] Research and Development - Research and development expenses for Q3 2022 totaled ¥14,363,169.94, which is an increase of 110.81% year-on-year, accounting for 23.65% of operating revenue[6] - Research and development expenses for the third quarter of 2022 amounted to ¥48,474,165.11, significantly higher than ¥22,863,891.32 in the same period last year, indicating a focus on innovation[21] - The company emphasized its commitment to innovation and increased investment in R&D to support future growth[9] Cash Flow and Investments - The cash flow from operating activities for the year-to-date was ¥41,705,251.06, reflecting a decrease of 12.41%[6] - The cash flow from operating activities for the first three quarters of 2022 was ¥269,304,347.99, slightly down from ¥274,384,819.73 in the same period of 2021[25] - The net cash flow from operating activities for Q3 2022 was $41,705,251.06, a decrease of 12.5% compared to $47,612,735.73 in Q3 2021[26] - Total cash inflow from investment activities was $1,132,069,411.74, significantly up from $524,545,392.07 in the previous year, indicating a strong investment recovery[26] - The net cash flow from investment activities was -$924,347,210.40, compared to -$72,752,916.76 in Q3 2021, reflecting increased investment expenditures[27] - Cash inflow from financing activities totaled $837,640,608.04, with a net cash flow of $825,982,889.10, a substantial improvement from -$59,204,089.88 in the same quarter last year[27] - The company reported a total cash outflow from investment activities of $2,056,416,622.14, compared to $597,298,308.83 in the previous year, highlighting aggressive investment strategies[26] Other Financial Metrics - The weighted average return on equity for Q3 2022 was 1.70%, an increase of 0.39 percentage points year-on-year[6] - The company's cash and cash equivalents were reported at ¥469,207,724.00, slightly down from ¥479,743,524.21 at the end of 2021[14] - The trading financial assets surged to ¥983,038,475.22, compared to only ¥87,245,837.05 at the end of 2021, indicating a growth of over 1,000%[14] - Accounts receivable increased to ¥71,063,150.43 from ¥4,129,898.69, reflecting a growth of approximately 1,620%[14] - The company's inventory stood at ¥47,039,747.51, compared to ¥43,627,428.64 in the previous year, showing a growth of approximately 9.3%[16] - Non-current assets totaled ¥163,770,967.47, an increase from ¥150,046,755.56, representing a growth of about 9.3%[16] - The company reported a significant increase in other receivables, which rose to ¥4,014,471.23 from ¥267,225.80, a growth of approximately 1,400%[14] - The company’s long-term equity investments were valued at ¥1,001,147.68, indicating a new investment strategy[16] Strategic Insights - The company has not disclosed any new product developments or market expansion strategies in the current report[14]